Charlie Ormond

Junior biotech Neuren Pharmaceuticals has signed an expanded licensing deal with its US distribution partner Acadia to expand the sale of its drug Daybue to global markets, pushing its stock price up by 16.24% today, trading at $13.53 per share.

Alliance Airlines shares soared today, rising by 13.43% after the company announced it has surpassed the top end of its profit guidance by $1.69 million and shared plans for expansion of its fleet of E190s.

KMD Brands announced profit guidance of EBITDA between $105–110 million, with record sales surpassing $1 billion, a first for the company. Shares were down by 8.76% despite the positive news as investors remained wary of early signs of poor winter sales.

Energy One laid rumours to rest today, announcing it will meet profit guidance for the 2HFY23, with an expected EBITDA of $12.3 million for the entire financial year. Shares were up 5.11% after the news, trading at 19 cents per share.

Clinical drug development company Emyria Ltd has announced the beginning of phase 2B recruitment of patients for an MDMA-assisted clinical PTSD trial after Australia recently rescheduled the drug.

CSR announced they have entered into an agreement to acquire long-term customer Woven Image for $43 million. The deal will broaden CSR’s range to include acoustic-focused products for commercial environments.

United Malt shares jump 8.98% this afternoon after announcing Malteries Soufflet signed a deal to buy out the craft beer and distillery producer for $5 per share. The deal still needs sign-off but could be a big move for malt producers worldwide.

Integrated services giant Downer Edi announced today that it had secured a $4.6 billion contract with the QLD Government to build and maintain 65 new trains for Brisbane. The announcement saw Downers shares rise by 2.41%, trading at $4.035 per share.